<DOC>
	<DOCNO>NCT01144143</DOCNO>
	<brief_summary>The purpose study determine anti-inflammatory drug , call infliximab , reduce inflammation synovial lining patient early stage osteoarthritis knee . It also help determine study medication decrease accumulation synovial fluid prevents cartilage breakdown .</brief_summary>
	<brief_title>Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab</brief_title>
	<detailed_description>This unbalanced randomize , double-blind pilot study Infliximab ( 100 mg ) , placebo ( 100 mg ) Methylprednisolone acetate ( 80 mg ) . A total 16 subject randomize ; 8 subject randomize receive infliximab , 4 subject randomize receive placebo 4 additional subject randomize receive Methylprednisolone acetate . Subjects see screen , day 0 , day 14 , day 28 day 56 . After study drug injection day 0 , patient return follow-up visit approximately 2 week , 1 2 month order obtain clinical endpoint measure total 10 week . Outcome measure include blood test , MRI , ultrasound , synovial lining tissue biopsy questionnaires adverse event .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1 . Adults ≥ age 35 ≤ age 85 . 2 . Painful knee 360 month . 3 . VAS joint pain score great 30 mm ( scale 0100 ) 4 . Knee radiograph show minimal moderate change ( early OA ) . 5 . No NSAID therapy least one week . 6 . Have capacity understand sign inform consent form . 7 . Gender : Male female 8 . Women must postmenopausal ( menstrual period minimum 1 year ) surgically sterilize negative serum pregnancy test entry study . Men must agree use adequate birth control study 6 month infusion study agent . 9 . Men woman childbearing potential must use adequate birth control measure ( e.g. , abstinence , oral contraceptive , intrauterine device , barrier method spermicide , implantable injectable contraceptive surgical sterilization ) duration study continue precaution 6 month receive last infusion . 10 . The screen laboratory test result must meet follow criterion 1 . WBC ( white blood cell count ) : &gt; 3.5/uL 2 . Hemoglobin : &gt; 10 gm/dl 3 . Platelets : &gt; 100,000/ul 4 . Serum Creatinine : &lt; 1.8 5 . SGPT ( ALT alanine aminotransferase ) &lt; 3 time ULN 6 . UA ( urinalysis ) microscopic exam : WNL 7 . Negative test HbsAg hepatitis C Ab 8 . PT/PTT : WNL 11 . Are consider eligible accord follow TB screen criterion : 1 . Have history latent active TB prior screen . An exception make subject history latent TB ( define purpose study positive result either tuberculin skin test QuantiFERONTB Gold test prior screen ) documentation complete adequate treatment regimen latent TB within 3 year prior first administration study agent protocol . Adequate treatment latent TB define accord local country guideline immunocompromised patient . If local guideline immunocompromised patient exist , US guideline must follow . It responsibility investigator verify adequacy previous antiTB treatment provide appropriate documentation . 2 . Have sign symptom suggestive active TB upon medical history and/or physical examination . 3 . Have recent close contact person active TB , contact , refer physician specialize TB undergo additional evaluation , warrant , receive appropriate treatment latent TB prior simultaneously first administration study agent . 4 . Within 1 month prior first administration study agent , either negative diagnostic TB test result ( defined negative tuberculin skin test negative QuantiFERONTB Gold test , outline Attachment 3 Attachment 4 , respectively ) , newly identify positive diagnostic TB test result ( define either positive tuberculin skin test positive QuantiFERONTB Gold test ) screen active TB rule appropriate treatment latent TB initiate either prior simultaneously first administration study agent . The tuberculin skin test QuantiFERONTB Gold test require screening subject history latent TB documentation complete adequate treatment describe Inclusion Criterion 12a . Furthermore , subject require initiate additional treatment latent TB . 5 . Have chest radiograph ( posterioranterior lateral view ) , take within 3 month prior first administration study agent read qualified radiologist , evidence current active TB old inactive TB . 1 . Moderate Severe OA , determine severe joint space narrowing ( Kellgren grade IV ) ( 7 ) medial lateral compartment 2 . Insulindependent diabetes mellitus . 3 . Systemic inflammatory illness , e.g . rheumatoid arthritis . 4 . Intraarticular injection within 3 month . 5 . Prior treatment infliximab antiTNF drug . 6 . Acute injury knee ( &lt; 2 week ) 7 . Women pregnant , nursing , plan pregnancy within 6 month last infusion ( include father 's plan father child within 6 month last infusion ) . 8 . Have previous treatment monoclonal antibody antibody fragment . 9 . History receive human/murine recombinant product know allergy murine product . A known allergy murine product definitely exclusion criterion 10 . Documentation positive test hepatitis B surface antigen hepatitis C. 11 . Have history alcohol substance abuse within precede 6 month , opinion investigator , may increase risk associate study participation study agent administration , may interfere interpretation result . 12 . Have know history serious infection ( e.g. , hepatitis , pneumonia , pyelonephritis ) previous 3 month . 13 . Have opportunistic infection ( e.g. , herpes zoster [ shingle ] , cytomegalovirus , Pneumocystis carinii , aspergillosis , histoplasmosis , mycobacteria TB ) within 6 month prior screen 14 . Currently receive Coumadin , Ticlid , Plavix , heparin/heparin analog within 7 day prior synovial biopsy . 15 . Currently receive aspirin within 7 day prior synovial biopsy . 16 . Have chest radiograph screening show evidence malignancy infection . 17 . Have history lymphoproliferative disease , include lymphoma sign suggestive possible lymphoproliferative disease lymphadenopathy unusual size location ( e.g. , node posterior triangle neck , infraclavicular , epitrochlear , periaortic area ) , splenomegaly . 18 . Currently know malignancy history malignancy within previous 5 year , exception basal cell squamous cell carcinoma skin fully excise evidence recurrence well carcinoma situ cervix . 19 . Have current sign symptom severe , progressive uncontrolled renal , hepatic , hematologic , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral disease . 20 . Are unable unwilling undergo multiple venipuncture poor tolerability lack easy access . 21 . Use investigational drug within 30 day prior screen within 5 halflives investigational agent , whichever longer . 22 . Presence transplant solid organ ( exception corneal transplant &gt; 3 month prior screen ) . 23 . Have concomitant diagnosis history congestive heart failure Grade IIIIV . 24 . Have nontuberculous mycobacterial infection opportunistic infection ( e.g. , cytomegalovirus , Pneumocystis carinii , aspergillosis ) within 6 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Mild moderate osteoarthritis knee</keyword>
</DOC>